Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 3/20 | 0.79 |
| ▸ | MAOB | P27338 | 6/20 | 0.66 |
| ▸ | APP | P05067 | 4/20 | 0.66 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.55 |
| ▸ | OSBP | P22059 | 1/20 | 0.52 |
| ▸ | PTGES | O14684 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4614966 | 1.00 | BACE1 (0.79) | BACE1MAOBAPPPTPN1OSBP | |
| SCHEMBL29352109 | 1.00 | BACE1 (0.79) | BACE1MAOBAPPPTPN1OSBP | |
| SCHEMBL14502407 | 0.89 | BACE1 (1.00) | BACE1MAOBAPPPTPN1OSBP | |
| Sargahydroquinoic Acid SCHEMBL14212076 | 0.89 | BACE1 (1.00) | BACE1MAOBAPPPTPN1OSBP | |
| SCHEMBL3822074 | 0.88 | BACE1 (0.64) | BACE1MAOBAPPPTPN1KMT2A | |
| SCHEMBL3822078 | 0.88 | BACE1 (0.64) | BACE1MAOBAPPPTPN1KMT2A | |
| SCHEMBL5361667 | 0.87 | BACE1 (0.93) | BACE1MAOBAPPPTPN1OSBP | |
| SCHEMBL14502405 | 0.87 | BACE1 (0.93) | BACE1MAOBAPPPTPN1OSBP | |
| SCHEMBL5361663 | 0.87 | BACE1 (0.93) | BACE1MAOBAPPPTPN1OSBP | |
| SCHEMBL10494097 | 0.87 | OSBP (0.64) | BACE1MAOBAPPPTPN1OSBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348167-B2 | Increase in the vitamin E content in organisms due to an increase in the tyrosine aminotransferase activity | SUNGENE GMBH & CO. KGAA (DE) | 2008-03-25 | — | — | US | disclosed |
| US-7332649-B2 | Changing the fine chemical content in organisms by genetically modifying the shikimate pathway | SUNGENE GMBH & CO. KGAA (DE) | 2008-02-19 | — | — | US | disclosed |
| US-20060057687-A1 | Changing the fine chemical content in organisms by genetically modifying the shikimate pathway | SUNGENE GMBH & CO., KGAA (DE) | 2006-03-16 | — | — | US | disclosed |
| US-20040086989-A1 | Increase in the vitamin e content in organisms due to an increase in the tyrosine aminotransferase activity | SUNGENE GMBH & CO. KGAA (DE) | 2004-05-06 | — | — | US | disclosed |
| WO-2003047547-A2 | PRENYLTRANSFERASE FROM PLANTS | SUNGENE GMBH & CO. KGAA (DE) | 2003-06-12 | — | — | WO | disclosed |
| US-20030084479-A1 | Homogentisate phytyl transferase | SUNGENE GMBH & CO. KGAA (DE) | 2003-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060057687-A1 | Changing the fine chemical content in organisms by genetically modifying the shikimate pathway | SQLE, PCK1, PGK1 | BACE1 4335/4885MAOB 1384/4885APP 4029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.